Structure

InChI Key CXGTZJYQWSUFET-IBGZPJMESA-N
Smiles CCO[C@@H](Cc1ccc(OCCc2ccc(OS(C)(=O)=O)cc2)cc1)C(=O)O
InChI
InChI=1S/C20H24O7S/c1-3-25-19(20(21)22)14-16-6-8-17(9-7-16)26-13-12-15-4-10-18(11-5-15)27-28(2,23)24/h4-11,19H,3,12-14H2,1-2H3,(H,21,22)/t19-/m0/s1

Physicochemical Descriptors

Property Name Value
Molecular Formula C20H24O7S
Molecular Weight 408.47
AlogP 2.68
Hydrogen Bond Acceptor 6.0
Hydrogen Bond Donor 1.0
Number of Rotational Bond 11.0
Polar Surface Area 99.13
Molecular species ACID
Aromatic Rings 2.0
Heavy Atoms 28.0

Bioactivity

Mechanism of Action Action Reference
Peroxisome proliferator-activated receptor alpha agonist AGONIST PubMed PubMed Wikipedia
Protein: Peroxisome proliferator-activated receptor gamma

Description: Peroxisome proliferator-activated receptor gamma

Organism : Homo sapiens

P37231 ENSG00000132170
Protein: Peroxisome proliferator-activated receptor alpha

Description: Peroxisome proliferator-activated receptor alpha

Organism : Homo sapiens

Q07869 ENSG00000186951
Assay Description Organism Bioactivity Reference
Receptor binding affinity to human Peroxisome proliferator activated receptor gamma against [3H]ragalitazar radioligand Homo sapiens 350.0 nM
Binding affinity for murine peroxisome proliferator activated receptor gamma Mus musculus 200.0 nM
Effective concentration against murine peroxisome proliferator activated receptor gamma in Gal4 transactivation assay Mus musculus 250.0 nM
Displacement of [3H]Rosiglitazone from human PPARgamma Homo sapiens 18.0 nM
Agonist activity at human PPARalpha by GAL4 transactivation assay Homo sapiens 414.0 nM
Agonist activity at human PPARalpha at 100 uM by GAL4 transactivation assay relative to WY 14,643 Homo sapiens 37.0 nM
Inhibition of PPARalpha at 50 uM None 55.5 %
Inhibition of PPARgamma at 1 uM None 59.4 %
Agonist activity at human PPARalpha ligand binding domain expressed in human HepG2 cells co-transfected with PPRE3-TK-luc assessed as induction of beta-galactosidase activity by transactivation assay Homo sapiens 820.0 nM
Agonist activity at human PPARgamma ligand binding domain expressed in human HepG2 cells co-transfected with PPRE3-TK-luc assessed as induction of beta-galactosidase activity by transactivation assay Homo sapiens 13.0 nM
Agonist activity at human PPARgamma expressed in african green monkey CV-1 co-transfected with GAL4 by by dual-glo luciferase reporter gene assay Homo sapiens 704.0 nM
Agonist activity at human PPARgamma ligand binding domain expressed in african green monkey CV1 cells co-transfected with fused Gal4-DBD by transactivation assay Homo sapiens 704.0 nM
Agonist activity at GAL4N fused human PPARgamma LBD expressed in HEK293 cells co-expressing TK-MH100x4-Luc after 24 hrs by luciferase reporter gene assay Homo sapiens 360.0 nM
Agonist activity at 3' GAL4 DNA binding domain fused mouse PPARgamma LBD expressed in U-2 OS cells after 40 hrs by luciferase reporter gene assay Mus musculus 250.0 nM
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of Caco-2 cells at 10 uM after 48 hours by high content imaging Homo sapiens -3.96 %
SARS-CoV-2 3CL-Pro protease inhibition percentage at 20µM by FRET kind of response from peptide substrate Severe acute respiratory syndrome coronavirus 2 9.956 %
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging Chlorocebus sabaeus 0.04 % Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging Chlorocebus sabaeus 0.04 %

Cross References

Resources Reference
ChEMBL CHEMBL282686
DrugBank DB06536
FDA SRS 6734037O3L
PDB AZ2
PubChem 208901
SureChEMBL SCHEMBL16594
ZINC ZINC000001550769